{"Clinical Trial ID": "NCT00574587", "Intervention": ["INTERVENTION 1:", "Strata A: VR-Paclitaxel-Trastuzumab", "Strata A: Vorinostat 200 (Dose Level 1) or 300 mg (Dose Level 2) orally on days 1 to 3 plus paclitaxel weekly 80 mg x 12 weeks and trastuzumab 4 mg/kg followed by 2 mg/kg x 12 weeks followed by doxorubicin 60 mg/m2 -cyclophosphamide 600 mg/m2 every 2 weeks x 8 weeks followed by surgery", "INTERVENTION 2:", "Stratum B: VR-Paclitaxel-Trastuzumab", "Stratum B: 300 mg orally on days 1 to 3 plus paclitaxel weekly 80 mg x 12 weeks and trastuzumab 4 mg/kg followed by 2 mg/kg x 12 weeks followed by doxorubicin 60 mg/m2 -cyclophosphamide 600 mg/m2 every 2 weeks x 8 weeks followed by surgery"], "Eligibility": ["Incorporation criteria:", "The breast adenocarcinoma, confirmed histologically or cytologically, is associated with the following stages: IIB, IIIA, IIIB or IIIC.", "Tumors should be positive Her2/neu", "No prior chemotherapy, radiation therapy or definitive therapeutic surgery", "- Exclusion criteria:", "- May not receive other investigative officers", "\u2022 Uncontrolled intercurrent disease"], "Results": ["Performance measures:", "Recommended Phase II dose of Vorinostat in combination with paclitaxel/trastuzumab weekly", "Dose limiting toxicity during cycle 1", "Duration: 3 weeks", "Results 1:", "Title of arm/group: Strata A: VR-Paclitaxel-Trastuzumab", "Description of the arm/group: Strata A: Vorinostat 200 (Level 1 dose) or 300 mg (Level 2 dose) orally on days 1 to 3 plus paclitaxel weekly 80 mg x 12 weeks and trastuzumab 4 mg/kg then 2 mg/kg x 12 weeks followed by doxorubicin 60 mg/m2 -cyclophosphamide 600 mg/m2 every 2 weeks x 8 weeks followed by surgery", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measurement: mg 300", "Results 2:", "Title of arm/group: Stratum B: VR-Paclitaxel-Trastuzumab", "Description of the arm/group: Stratum B: 300 mg orally on days 1 to 3 plus paclitaxel weekly 80 mg x 12 weeks and trastuzumab 4 mg/kg followed by 2 mg/kg x 12 weeks followed by doxorubicin 60 mg/m2 -cyclophosphamide 600 mg/m2 every 2 weeks x 8 weeks followed by surgery", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measurement: mg 300"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/3 (0.00 per cent)", "- Cardiac tamponade 0/3 (0.00 %)", "- Congestive heart failure 0/3 (0.00 %)", "Pulmonary embolism 0/3 (0.00 %)", "Adverse Events 2:", "Total: 2/23 (8.70 per cent)", "- Cardiac tamponade 0/23 (0.00 %)", "Congestive heart failure 1/23 (4.35%)", "1/23 (4.35%)"]}